Market Data
Market Cap₹305.06 Cr.
52W High₹103.2
Current Price₹69.65
52W Low₹60.45
Down from 52W High32.5 %
Face Value₹10
Performance
ROCE7.5 %
ROE6.69 %
EPS (TTM)₹2.19
EPS Prev Qtr₹2.04
EPS Last Year₹2.8
EBITDA Qtr₹11.39 Cr.
Book Value₹76
Financial Health
Debt/Equity0.15
Debt/Profit2.21
Total Assets₹518.743 Cr.
Promoter Holding4.53 %
Earning Power5.44 %
Valuation
Stock P/E13.74
Industry P/E33.3
Price to Book0.92
Price to Sales0.98
Graham Number₹92.93
Key Metrics
__derived
1
Face Value
₹10
About Astal Laboratories Ltd
Healthcare · Pharmaceuticals
Astal Laboratories Ltd is listed on NSE in the Healthcare / Pharmaceuticals sector. Face value ₹10. Market cap ₹305.06 Cr.
Price Chart
Peer Comparison
| Name | CMP | P/E | Market Cap | Div Yield | NP Qtr | Qtr Profit Var% | Sales Qtr | Qtr Sales Var% | ROCE% | Debt/Eq |
|---|---|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | - | 36.9 | ₹4,46,276.3 Cr | 0.86% | ₹12,172.7 Cr | - | ₹59,910.52 Cr | - | 18.72% | 0.05 |
| Divis Laboratories Ltd | - | 85.97 | ₹2,51,531.48 Cr | 0.32% | ₹2,925 Cr | - | ₹11,230 Cr | - | 23.04% | 0 |
| Torrent Pharmaceuticals Ltd | - | 78.4 | ₹1,86,956.51 Cr | 0.77% | ₹2,156 Cr | - | ₹15,723 Cr | - | 15.1% | 1.76 |
| Zydus Lifesciences Ltd | - | 26.64 | ₹1,19,221.66 Cr | 0.08% | ₹4,492.2 Cr | - | ₹28,591.7 Cr | - | 16.76% | 0.43 |
| Cipla Ltd | - | 33.13 | ₹1,11,725.01 Cr | 0.94% | ₹3,364.84 Cr | - | ₹28,324.4 Cr | - | 13.24% | 0.01 |
| Laurus Labs Ltd | - | 98.01 | ₹1,07,271.96 Cr | 0.06% | ₹1,090.76 Cr | - | ₹7,269.64 Cr | - | 20.79% | 0.45 |
| Mankind Pharma Ltd | - | 51.42 | ₹1,05,107.48 Cr | 0.04% | ₹2,067.57 Cr | - | ₹14,737.88 Cr | - | 13.95% | 0.38 |
| Dr Reddys Laboratories Ltd | - | 32.31 | ₹1,04,334.48 Cr | 0.64% | ₹3,183.3 Cr | - | ₹33,227.9 Cr | - | 10.05% | 0.17 |
| Aurobindo Pharma Ltd | - | 26.61 | ₹97,986.86 Cr | 0.23% | ₹3,710.8 Cr | - | ₹34,935.29 Cr | - | 12.75% | 0.2 |
| Lupin Ltd | - | 16.63 | ₹94,189.9 Cr | 0.87% | ₹5,550.99 Cr | - | ₹29,966.58 Cr | - | 27.95% | 0.26 |
| Glenmark Pharmaceuticals Ltd | - | 37.59 | ₹67,587.09 Cr | 0.1% | ₹1,797.81 Cr | - | ₹17,736.56 Cr | - | 24.78% | 0.25 |
| Alkem Laboratories Ltd | - | 29.02 | ₹62,609.02 Cr | 1.01% | ₹2,206.3 Cr | - | ₹15,081.28 Cr | - | 19.75% | 0.12 |
| Biocon Ltd | - | 111.18 | ₹61,602.44 Cr | 0.13% | ₹416.4 Cr | - | ₹17,321.1 Cr | - | 2.87% | 0.43 |
| Abbott India Ltd | - | 35.88 | ₹57,939.73 Cr | 1.74% | ₹1,614.68 Cr | - | ₹7,004.38 Cr | - | 45.73% | 0 |
| Gland Pharma Ltd | - | 43.62 | ₹49,299.85 Cr | 0.67% | ₹1,128.8 Cr | - | ₹6,725.3 Cr | - | 15.21% | 0.02 |
| Ipca Laboratories Ltd | - | 36.55 | ₹49,280.78 Cr | 0.31% | ₹1,379.76 Cr | - | ₹10,125.58 Cr | - | 21.48% | 0.09 |
| Anthem Biosciences Ltd | - | 85 | ₹49,084.9 Cr | 0.23% | ₹575.95 Cr | - | ₹2,002.34 Cr | - | 25.5% | 0.02 |
| Glaxosmithkline Pharmaceuticals Ltd | - | 44.95 | ₹47,217.7 Cr | 2.05% | ₹1,068.15 Cr | - | ₹3,954.94 Cr | - | 64.07% | 0 |
| Ajanta Pharma Ltd | - | 39.17 | ₹44,452.1 Cr | 0.79% | ₹1,134.88 Cr | - | ₹5,776.17 Cr | - | 31.81% | 0.05 |
| J B Chemicals & Pharmaceuticals Ltd | - | 53.3 | ₹38,730.77 Cr | 0.39% | ₹709.46 Cr | - | ₹4,147.79 Cr | - | 23.03% | 0 |
Quarterly Results
| Mar 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|
| Sales | 23.47 | 52.24 | 134.05 | 100.94 |
| ↳ QoQ Growth | - | +122.6% | +156.6% | -24.7% |
| Expenses | 19.39 | 48.81 | 124.72 | 89.55 |
| Operating Profit | 4.08 | 3.43 | 9.33 | 11.39 |
| OPM % | 17.38% | 6.57% | 6.96% | 11.28% |
| Other Income | 0.04 | 0.04 | 0.1 | 0.14 |
| Interest | 0.27 | 0.33 | 1.09 | 1.18 |
| Depreciation | 0.1 | 0.12 | 0.86 | 0.86 |
| EBITDA | 4.18 | 3.55 | 10.19 | 12.25 |
| EBITDA Margin % | 17.81% | 6.8% | 7.6% | 12.14% |
| Profit Before Tax | 3.85 | 3.13 | 8.34 | 10.35 |
| Tax % | 28.57% | 24.6% | 7.91% | 8.99% |
| Net Profit | 2.74 | 2.36 | 7.68 | 9.42 |
| ↳ QoQ Growth | - | -13.9% | +225.4% | +22.7% |
| EPS | 2.8 | 2.19 | 2.04 | 2.19 |
Balance Sheet
| Mar 2025 | Mar 2026 | |
|---|---|---|
| Equity Capital | 9.85 | 42.2312 |
| Reserves | 26.15 | 289.456 |
| Borrowings | 13.27 | 49.08 |
| Other Liabilities | 14.07 | 137.98 |
| Total Liabilities | 63.34 | 518.7434 |
| Fixed Assets | 11.44 | 64.4595 |
| CWIP | 0 | 0 |
| Investments | 0 | 203.2 |
| Other Assets | 51.9 | 251.08 |
| Total Assets | 63.34 | 518.7434 |
Cash Flows
| Mar 2026 | |
|---|---|
| Cash from Operating Activity | -17.6988 |
| Cash from Investing Activity | -2.1701 |
| Cash from Financing Activity | 2.5801 |
| Net Cash Flow | -17.2888 |
Shareholding Pattern
| Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|
| Promoters % | 18.19% | 4.7% | 4.53% |
| FIIs % | 0% | 0% | 0% |
| DIIs % | 0% | 0% | 0% |
| Public % | 73.06% | 80.1% | 80.88% |
| No. of Shareholders | 2,926 | 3,065 | 3,274 |